Hanmi Pharmaceutical Co., Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hanmi Pharmaceutical Co., Ltd.
Korean CDMO Industry Entering A Renaissance Or Growing Too Fast?
The Korean contract development and manufacturing industry is rapidly growing with more established firms and newcomers set to sharply expand capacities and diversify portfolios, but competition to secure relevant workforce in the country is also getting fiercer.
Korea Q4 Roundup: International Growth A Key Factor For Major Firms
Aside from record earnings reported by a number of Korean pharma companies, the industry saw a diverse range of headlines in the fourth quarter, including cross-border acquisitions and business diversification.
Next Potential Big ADC Player? Korean Firms Take It Up A Notch
Scrip takes a look at the increasingly competitive landscape of Korean antibody-drug conjugate developers, which are now vying to catch up with their global rivals in the hot area.
Korea’s Key Words For 2023: Regulatory Innovation, Digital Healthcare
The Pink Sheet’s roundup of key regulatory issues in Korea for 2022 and outlook for this year.
- Other Names / Subsidiaries
- Beijing Hanmi Pharmaceutical Co., Ltd.
- Hanmi Holdings Co., Ltd
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.